# Intra-Cellular Therapies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/intra-cellular-therapies

- Industry: Biotechnology
- Headquarters: Bedminster, US
- Website: www.intracellulartherapies.com
- Total disclosed funding: $14M
- Latest round: Series C (Oct 31, 2007)
- Investors on record: 3

## About

Based in New York, US, and founded by Sharon Mates (Chairman and CEO) in 2001, Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company developing target mechanism to counter the progression of Alzheimer's Disease. In January 2014, Intra-Cellular Therapies, Inc raised USD 107.49 million in an IPO, selling 6.14 million shares on the NASDAQ. Further in January 2022, the firm raised USD 400 million in a Private Placement selling 9.52 million shares on the NASDAQ. The firm trades under the ticker symbol ITCI. In January 2025, Johnson & Johnson, Inc. agreed to fully acquire Intra-Cellular Therapies, Inc. from Broadfin Capital, Tech Council Ventures, Alexandria Real Estate Equities, and Alafi Capital, for approximately USD 14.6 billion.

The company’s flagship product, CAPLYTA® (lumateperone), is FDA-approved for treating schizophrenia and bipolar depression, offering a unique mechanism of action that combines efficacy with a favorable safety profile. Intra-Cellular Therapies' pipeline includes: ITI-1284 ODT-SL for generalized anxiety and agitation in Alzheimer’s patients, ITI-333 for opioid use disorder and mood disorders, and the ITI-1500 series, featuring non-hallucinogenic psychedelics aimed at mood disorders. In addition to these, the company is advancing PDE1 inhibitors like lenrispodun (ITI-214) for Parkinson’s disease and ITI-1020 for cancer immunotherapy.

## Funding rounds

- Series C, Oct 31, 2007, $8M — Tech Council Ventures, Alafi Capital, Alexandria Real Estate Equities
- Series B, Jan 22, 2006, $6.2M — Alafi Capital, Alexandria Real Estate Equities

## Investors

- Alafi Capital (https://capitalatlas.ai/funds/alafi-capital) — Series B, Series C
- Alexandria Real Estate Equities — Series B, Series C
- Tech Council Ventures (https://capitalatlas.ai/funds/tech-council-ventures) — Series C